Novel Latency Reversal Agents for HIV-1 Cure

Annual Review of Medicine

Vol. 69:421-436 (Volume publication date January 2018)
First published as a Review in Advance on November 3, 2017
https://doi.org/10.1146/annurev-med-052716-031710

Abstract

Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate HIV-1 in infected individuals. This review describes current pharmacologic approaches to reactivate the latent reservoir so that infected cells can be recognized and targeted, with the ultimate goal of achieving an HIV-1 cure.

Keywords